Artikel ; Online: Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.
Cancer immunology, immunotherapy : CII
2021 Band 70, Heft 10, Seite(n) 2771–2780
Abstract: Background: Sarcopenia has been associated with negative clinical outcomes in cancer patients, particularly response to treatment and survival. The exponential growth in the use of immune checkpoint inhibitors (ICIs) has led to an increase in the ... ...
Abstract | Background: Sarcopenia has been associated with negative clinical outcomes in cancer patients, particularly response to treatment and survival. The exponential growth in the use of immune checkpoint inhibitors (ICIs) has led to an increase in the reporting of both adverse events in general (AEs) and immune-related adverse events (irAEs), which are unintended immune-related phenomenon that take place as a result of checkpoint blockade. However, there are no systematic reviews evaluating the relationship between sarcopenia and the risk of developing AEs and irAEs in cancer patients on ICI therapies. Methods: PubMed, MEDLINE, Embase, Cochrane and grey literature, repositories, websites Open Grey, Google Scholar, and abstracts of major international congresses were searched up to April 2020 for observational studies on sarcopenia and both AEs and irAEs in patients treated with ICIs. Study quality was assessed with The Newcastle-Ottawa quality assessment scale. PROSPERO registration number: CRD42020197178. Results: One hundred and thirteen discrete articles were identified. Seven studies were included after evaluation of the eligibility criteria. Important sources of heterogeneity including the specific cut-points defining sarcopenia, sample size, inclusion and exclusion criteria, treatment regimen, and baseline demographics were evaluated and accounted for accordingly. Conclusion: Most of the included studies showed an increased risk of AEs with use of ICIs in cancer patients with sarcopenia, and in the majority of these, the increase was statistically significant. Due to the small number of available studies and the expanding use of ICIs, additional research is warranted. |
---|---|
Mesh-Begriff(e) | Adult ; Aged ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Middle Aged ; Prospective Studies ; Retrospective Studies ; Sarcopenia/drug therapy |
Chemische Substanzen | Immune Checkpoint Inhibitors |
Sprache | Englisch |
Erscheinungsdatum | 2021-02-24 |
Erscheinungsland | Germany |
Dokumenttyp | Journal Article ; Systematic Review |
ZDB-ID | 195342-4 |
ISSN | 1432-0851 ; 0340-7004 |
ISSN (online) | 1432-0851 |
ISSN | 0340-7004 |
DOI | 10.1007/s00262-021-02888-6 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.A 1237: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.